Follow John on: A look at some of the major movers in London on Monday Scancell Holdings PLC (LON:SCLP) soared 55% to 21.25p, prompting the company to put out a statement about the share price movement. The developer of novel immunotherapies for the treatment of cancer and infectious disease noted the recent press coverage and the share price increase and referred shareholders to its interim results statement of January 29, where it gave a full update on the COVIDITY program and the goal of starting a Phase 1 clinical trial, to determine the safety and immune responses to the vaccine, as soon as possible during 2021.